These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39142721)

  • 1. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    Shin JI; Xu Y; Chang AR; Carrero JJ; Flaherty CM; Mukhopadhyay A; Inker LA; Blecker SB; Horwitz LI; Grams ME
    J Am Coll Cardiol; 2024 Aug; 84(8):683-693. PubMed ID: 39142721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Eneanya ND; Essien U; Julien H; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Netw Open; 2021 Apr; 4(4):e216139. PubMed ID: 33856475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
    Gregg LP; Ramsey DJ; Akeroyd JM; Jafry SA; Matheny ME; Virani SS; Navaneethan SD
    Am J Kidney Dis; 2023 Jul; 82(1):53-62.e1. PubMed ID: 36702340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.
    Somaili M; Oraibia O; Darraj M; Hassan A; Moafa E; Kulaybi A; Shubayli S; Moafa R; Mghfori G; Jaafari A; Somily M
    Curr Diabetes Rev; 2024; 20(4):e060723218471. PubMed ID: 37415371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.
    Ozaki AF; Ko DT; Chong A; Fang J; Atzema CL; Austin PC; Stukel TA; Tu K; Udell JA; Naimark D; Booth GL; Jackevicius CA
    CMAJ Open; 2023; 11(3):E494-E503. PubMed ID: 37311594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
    Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
    JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.
    Liu J; Su X; Hao Y; Liu J;
    Sci Rep; 2024 Aug; 14(1):18290. PubMed ID: 39112571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sodium-glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease.
    Alkhunaizi AM; Khairalla H
    Saudi J Kidney Dis Transpl; 2023 Sep; 34(5):468-473. PubMed ID: 38995308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
    Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
    Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.
    Lau D; Pannu N; Yeung RO; Scott-Douglas N; Klarenbach S
    CMAJ Open; 2023; 11(1):E101-E109. PubMed ID: 36720493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
    Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
    EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Fralick M; Chen SK; Patorno E; Kim SC
    Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
    Bermudez SR; Anderson JR; Bos AJ; Ray GM
    Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.